Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 449

Sort by

Sort Order Select

Journal Articles

CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)

Shree Allada, Richa Parikh, Ajay Nooka, Sagar Lonial, Nisha Joseph

Blood (2025) 146 (Supplement 1): 4078.

https://doi.org/10.1182/blood-2025-4078

Published: 2025

Journal Articles

Belantamab mafodotin (belamaf) ocular events are manageable and reversible with dose modifications guided by standard assessments

Sagar Lonial, Paul Richardson, Craig Cole, Asim Farooq, Meghan Berkenstock, Julie Byrne, Sumita Roy-Ghanta, Rachel Rogers, Amy Phillips-Jones, Astrid McKeown, Natalie Afshari

Blood (2025) 146 (Supplement 1): 4055.

https://doi.org/10.1182/blood-2025-4055

Published: 2025

Journal Articles

Health-related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM): An exploratory analysis of overall quality of life in dreamm-7

Sagar Lonial, Craig Cole, Angely Loubert, Laurine Bunod, Manal M'Hari, Pralay Mukhopadhyay, Sandhya Sapra, Molly Purser, Jacqueline Nielsen, Benga Kazeem, Farrah Pompilus, Paul Richardson

Blood (2025) 146 (Supplement 1): 4029.

https://doi.org/10.1182/blood-2025-4029

Published: 2025

Journal Articles

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Blood (2025) 146 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2025-4026

Published: 2025

Journal Articles

Mapping the immune checkpoint receptor-ligand landscape in newly diagnosed multiple myeloma may help prioritize patients for immune checkpoint inhibitor therapy

Steven Foltz, Reyka Jayasinghe, MMRF Immune Atlas Network, David Avigan, Samir Parekh, Ravi Vij, Shaji Kumar, Taxiarchis Kourelis, Sagar Lonial, Hearn Cho, Ioannis Vlachos, Sacha Gnjatic, Li Ding, Manoj Bhasin, Chaitanya Acharya, Alexander Gout, George Mulligan

Blood (2025) 146 (Supplement 1): 4024.

https://doi.org/10.1182/blood-2025-4024

Published: 2025

Journal Articles

Equalizing access to chimeric antigen receptor (CAR) T-cell therapies for myeloma patients

Ajay Nooka, Nishi Shah, Lawrence Boise, Sagar Lonial

Blood (2025) 146 (Supplement 1): 2823.

https://doi.org/10.1182/blood-2025-2823

Published: 2025

Journal Articles

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

Om Raval, Lilly Gu, Nisha Joseph, Craig Hofmeister, Vikas Gupta, Richa Parikh, Nishi Shah, Sagar Lonial, Ajay Nooka, Jonathan Kaufman

Blood (2025) 146 (Supplement 1): 2812.

https://doi.org/10.1182/blood-2025-2812

Published: 2025

Journal Articles

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

Sara Scott, Ajay Nooka, Jonathan Kaufman, Craig Hofmeister, Vikas Gupta, Richa Parikh, Nishi Shah, Sagar Lonial, Nisha Joseph

Blood (2025) 146 (Supplement 1): 2811.

https://doi.org/10.1182/blood-2025-2811

Published: 2025

Journal Articles

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

Blood (2025) 146 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2025-2179

Published: 2025

Journal Articles

Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)

Nisha Joseph, Richa Parikh, Shree Allada, Vikas Gupta, Craig Hofmeister, Nishi Shah, Jonathan Kaufman, Sagar Lonial, Ajay Nooka

Blood (2025) 146 (Supplement 1): 2301.

https://doi.org/10.1182/blood-2025-2301

Published: 2025

Journal Articles

NSD2 expression remodels DNA methylation, creating a targetable epigenetic dependency in t(4;14) multiple myeloma

Anna Baj, Jonathan Patton, Robert Chavez, Shannon Matulis, Doris Powell, Mala Shanmugam, Arun Wiita, Constantine Mitsiades, Jonathan Keats, Jonathan Licht, Sagar Lonial, Lawrence Boise, Benjamin Barwick

Blood (2025) 146 (Supplement 1): 572.

https://doi.org/10.1182/blood-2025-572

Published: 2025

Journal Articles

Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial

Anna Sureda Balarí, Abdullah Khan, Albert Oriol, Mercedes Gironella Mesa, Faiz Anwer, Cristina Encinas, Brea Lipe, Paula Rodriguez-Otero, Ping Chen, Hongxia Lin, Kexin Jin, Thomas Solomon, Lilia Taningco, Olumoroti Aina, Paulo Maciag, Sagar Lonial

Blood (2025) 146 (Supplement 1): 5810.

https://doi.org/10.1182/blood-2025-5810

Published: 2025

Journal Articles

Impact of extrinsic heme on adoptive T cell therapy

Dejah Blake, Pulkit Gupta, Remya Nair, Ruby Freeman, Heather Lin, Sagar Lonial, Benjamin Barwick, Ajay Nooka, Jean Koff, Sarwish Rafiq, Mala Shanmugam

Blood (2025) 146 (Supplement 1): 7628.

https://doi.org/10.1182/blood-2025-7628

Published: 2025

Journal Articles

Commpass explorer: An interactive platform to explore clinico-genomic data from newly diagnosed multiple myeloma patients from the commpass observational trial

Wanxing Zhang, Chaitanya Acharya, Steven Foltz, MMRF Immune Atlas Network, David Avigan, Samir Parekh, Ravi Vij, Shaji Kumar, Taxiarchis Kourelis, Sagar Lonial, Hearn Cho, Ioannis Vlachos, Sacha Gnjatic, Li Ding, Manoj Bhasin, George Mulligan

Blood (2025) 146 (Supplement 1): 7470.

https://doi.org/10.1182/blood-2025-7470

Published: 2025

Journal Articles

An exploratory analysis of health-related quality of life measures with belantamab mafodotin in combination with pomalidomide and dexamethasone (BPd) in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in dreamm-8

Paul Richardson, Craig Cole, Angely Loubert, Laurine Bunod, Manal M'Hari, Pralay Mukhopadhyay, Sandhya Sapra, Molly Purser, Benga Kazeem, Farrah Pompilus, Sagar Lonial

Blood (2025) 146 (Supplement 1): 2284.

https://doi.org/10.1182/blood-2025-2284

Published: 2025

Journal Articles

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

Ajay Nooka, Nisha Joseph, Madhav Dhodapkar, Vikas Gupta, Craig Hofmeister, Manali Rupji, Bryan Burton, Hafsa Ahmed, Darrian Linton, Stephen Noga, Thomas Lin, Lawrence Boise, Jonathan Kaufman, Sagar Lonial

Blood (2025) 146 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2025-5843

Published: 2025

Journal Articles

Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial

Danny Jeyaraju, Sanhita Sengupta, Paulo Maciag, Anna Sureda Balarí, Niels W.C.J. van de Donk, Sagar Lonial, Anita Gandhi, Michael Amatangelo

Blood (2025) 146 (Supplement 1): 2255.

https://doi.org/10.1182/blood-2025-2255

Published: 2025

Journal Articles

Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries

Kiran Lakhani, Yu Zhang, Jonathan Keats, Vikas Gupta, Sagar Lonial, Nisha Joseph, Ajay Nooka, Benjamin Barwick, Lawrence Boise

Blood (2025) 146 (Supplement 1): 2251.

https://doi.org/10.1182/blood-2025-2251

Published: 2025

Journal Articles

The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial

Blood (2025) 146 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2025-1033

Published: 2025

Journal Articles

Evidence for pre-existing myeloma cells with a gene expression pattern associated with resistance to BCMA CAR T cells.

Angelica Amanso, Karanpreet Bhatia, Mackenzie Mekler, James Ackley, Pankoj Das, London Harper, Holly Lee, Madhav Dhodapkar, Stanley Riddell, Paola Neri, Nizar Bahlis, Sagar Lonial, Adam Marcus, Lawrence Boise

Blood (2025) 146 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2025-1031

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)

Belantamab mafodotin (belamaf) ocular events are manageable and reversible with dose modifications guided by standard assessments

Health-related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM): An exploratory analysis of overall quality of life in dreamm-7

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Mapping the immune checkpoint receptor-ligand landscape in newly diagnosed multiple myeloma may help prioritize patients for immune checkpoint inhibitor therapy

Equalizing access to chimeric antigen receptor (CAR) T-cell therapies for myeloma patients

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)

NSD2 expression remodels DNA methylation, creating a targetable epigenetic dependency in t(4;14) multiple myeloma

Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial

Impact of extrinsic heme on adoptive T cell therapy

Commpass explorer: An interactive platform to explore clinico-genomic data from newly diagnosed multiple myeloma patients from the commpass observational trial

An exploratory analysis of health-related quality of life measures with belantamab mafodotin in combination with pomalidomide and dexamethasone (BPd) in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in dreamm-8

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial

Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries

Evidence for pre-existing myeloma cells with a gene expression pattern associated with resistance to BCMA CAR T cells.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only